Posters

Clinical outcomes of a new non-diffractive presbyopia-correcting intraocular lens in Canada

Poster Details

First Author: S.Holland CANADA

Co Author(s):    A. Martinez                    

Abstract Details

Purpose:

To evaluate the effectiveness and safety of the new non-diffractive presbyopia-correcting intraocular lens (IOL), AcrySof® IQ Vivity (model DFT015) versus an aspheric monofocal IOL (model SN60WF) in the Canadian sub-population of a multicountry clinical trial.

Setting:

Six investigational sites in Canada.

Methods:

This prospective, multicentre, randomised, parallel-group, controlled, assessor- and patient-masked study included 6 cataract patients from Canada bilaterally implanted with DFT015 (n=39) or SN60WF (n=33). Refractive outcomes, binocular defocus curve and quality of vision (QoV Questionnaire, McAlinden) were assessed at Month 6.

Results:

DFT015 demonstrated ˃0.5D extended range of vision at 0.2 logMAR compared with SN60WF. The visual disturbances profile was similar between groups, with low rates (˂4%) of very bothersome and severe starbursts, halos and glare were reported in both groups.

Conclusions:

In the Canadian sub-population of a large study, the non-diffractive presbyopia-correcting IOL DFT015 provided patients with an extended range of vision, while maintaining a visual disturbance profile similar to that of an aspheric monofocal IOL. This results show that DFT015 exhibits the advantages of a multifocal IOL, but without the photic phenomena generally associated with diffractive IOLs.

Financial Disclosure:

is employed by a for-profit company with an interest in the subject of the presentation, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented